DATA GRAPHICS | Data Byte
FDA approves first DNA plasmid immunotherapy; NME tally reaches 47
Two October approvals push 2026 total past full-year 2025, with two months remaining
November 4, 2026 10:02 PM UTC
FDA approved the first plasmid DNA-based immunotherapy in October, granting accelerated approval to Inovio’s Voceryq doruxapapogene ralaplasmid and lalikinogene sifuplasmid.
The product, formerly INO-3107, was approved by CBER to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis, a rare manifestation of human papillomavirus (HPV) infection. Voceryq generates an immune response against against cells infected with HPV-6 or HPV-11. Inovio expects to begin shipments by year-end...